{"id":"W4386538802","doi":"10.1093/neuonc/noad137.005","title":"PL02.3.A NRG ONCOLOGY STUDY BN007: RANDOMIZED PHASE II/III TRIAL OF IPILIMIUMAB (IPI) PLUS NIVOLUMAB (NIVO) VS. TEMOZOLOMIDE (TMZ) IN MGMT-UNMETHYLATED (UMGMT) NEWLY DIAGNOSED GLIOBLASTOMA (NGBM)","year":2023,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Temozolomide; Medicine; Internal medicine; Hazard ratio; Clinical endpoint; Nivolumab; Oncology; Progression-free survival; Randomized controlled trial; Phases of clinical research; Dacarbazine; Surrogate endpoint; Cancer; Chemotherapy; Confidence interval; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001552341,0.001063267,0.001146054,0.0003562105,0.0003011944,0.0007780548,0.0009310658,0.001066927,0.01074667],"category_scores_gemma":[0.001051375,0.0005075556,0.001009683,0.0003889131,0.0007247681,0.0005712495,0.0003724805,0.002410586,0.001972565],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001039886,"about_ca_system_score_gemma":0.002452575,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001807831,"about_ca_topic_score_gemma":0.007370558,"domain_scores_codex":[0.9996252,0.0002260599,0.00001410339,0.00004492807,0.00003312504,0.00005663555],"domain_scores_gemma":[0.9996007,0.00007470045,0.00008396514,0.00002236169,0.00002380649,0.0001943645],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9235681,0.01150204,0.002374868,0.0006353406,0.0005299926,0.00009724763,0.00008027771,0.000710351,0.007627825,0.0004322799,0.007943368,0.04449829],"study_design_scores_gemma":[0.9289343,0.06330112,0.003097348,0.00005074087,0.0003218389,0.00007552591,0.00002955024,0.0005334961,0.0006727219,0.0003593749,0.002612053,0.00001200908],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9593598,0.003727476,0.001207798,0.002320329,0.0004370864,0.01256862,0.009731013,0.0004677093,0.01018002],"genre_scores_gemma":[0.9466284,0.003109302,0.004845909,0.00405357,0.0003217247,0.01678974,0.01188145,0.0001106896,0.01225923],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01074667,"threshold_uncertainty_score":0.03595126,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02744413339286474,"score_gpt":0.3433068402133076,"score_spread":0.3158627068204429,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}